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Abstract Glycogenin, the autocatalytic, self-glucosylating 
primer for glycogen synthesis by glycogen synthase, is presumed, 
in vivo, to use UDP-glucose as the source of the glucose residues 
it adds to itself. When we tested its ability to utilize other nucle- 
oside diphosphate glucoses, it emerged that purine nucleotides are 
not utilized but two pyrimidine nucleotides are used, in addition 
to UDP-glucose. These are CDP-glucose and TDP-glucose. 
CDP-glucose is utilized at 70% of the rate of UDP-glucose. 
While there is no evidence that CDP-glucose is a natural sub- 
strate for glycogenin, it has the advantage over UDP-glucose in 
that it can be used specifically to detect and assay glycogenin in 
the presence of glycogen synthase because CDP-glucose, unlike 
UDP-glucose, is not a substrate for the synthase. 
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side diphosphate glucoses and now report that TDP-glucose, 
and especially CDP-glucose, are substrates for glycogenin, the 
latter being specific, not utilized by glycogen synthase. 
2. Materials and methods 
2.1. Materials 
All biochemicals were from Sigma or Fischer Scientific Co. Recom- 
binant rabbit muscle wild-type, Phe 194 mutant and apo-glycogenins 
were prepared as by Alonso et al. [12 14]. 
2.2. Methods 
The experimental conditions employed inthe incubation of glycogen- 
ins with potential glucose donors are described in the legends to the 
figures. The HPLC fractionation procedure for the products of the 
intermolecular transglucosylation ofp-nitrophenyl c~-maltoside (Fig. l) 
is described in[13]. The self-glucosylating activity of recombinant wild- 
type glycogenin the presence and absence of CDP was measured as 
in [13]. 
1. Introduction 
When the self-glucosylating action of glycogenin was first 
detected in muscle and heart extracts, the glucose donor sub- 
strate used was UDP-glucose [1], the same as is used by glyco- 
gen synthase to extend the maltosaccharide primer chain that 
glycogenin creates on itself. When working with tissue extracts 
or partly purified preparations containing both glycogenin and 
synthase, it has been possible to distinguish between the two 
enzymes by virtue of the fact that the Km values of glycogenin 
and synthase for UDP-glucose differ by three orders of magni- 
tude [2M], although the form of synthase we have named pro- 
glycogen synthase is active at the same micromolar UDP-glu- 
cose concentration as is optimal for glycogenin [5]. Another 
distinction ispossible because glycogenin is activated by Mn 2+, 
while the synthases are activated by glucose 6P, and not vice 
versa [6-8]. 
It would, however, be useful if a specific glucose donor sub- 
strate could be found for glycogenin so as to permit a study of 
its behavior in presence of synthase, and to be able sequentially 
first to synthesize the primer and then, by the addition of 
UDP-glucose, to initiate glycogen synthesis proper. This would 
facilitate the study of the properties and function of the com- 
plex between glycogenin and synthase that Cohen and his col- 
leagues consider is necessary for glycogen synthesis [8,9]. 
A specific glycogenin substrate was reported by Meezan et 
al. [10]. This is UDPxylose. However, glycogenin will add only 
one xylose to itself. No further chain growth, either with UDP- 
xylose or UDP-glucose, takes place [11]. 
We have tested the commercially available range of nucleo- 
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3. Results and discussion 
We were led to the experiments reported here by considering 
our own results, and the results of others, on the inhibition of 
glycogenin by nucleotides. ATP at physiological concentration 
is a powerful inhibitor of native muscle glycogenin [11], but less 
so of recombinant muscle glycogenin [13,15]. UTP and UDP 
are more powerful inhibitors of recombinant glycogenin than 
is ATP [15]. These inhibitions occur at millimolar concentra- 
tions of nucleotide. CDP, by contrast, almost completely (93%) 
inhibits native kidney glycogenin at 25 ,uM concentration [16] 
and we now report hat this is about he same (90%) for recom- 
binant muscle glycogenin. 
Earlier we had observed that maltose inhibits the self-gluco- 
sylation of glycogenin [17]. Further study revealed that the 
'inhibition' was because the added sugar competes for the glu- 
cose transferred from UDP-glucose. The p-nitrophenyl ~-mal- 
tosaccharides and the ~-glucoside are even more potent han 
maltose [17], while, more recently, dodecyl fl-maltoside has 
been shown to be better still as an acceptor [18]. It was with the 
use of these acceptors that we were able to learn that the Phe t94 
and Thr 194 mutant forms of glycogenin which, lacking Tyr194not 
self-glucosylate, are nevertheless fully active in intermolecular 
transglucosylation t  these small molecule acceptors [12,13]. 
The inhibition of glycogenin by UTP and UDP [15] might be 
explained by their competing for the UDP-glucose binding site. 
Reasoning this, we asked whether CDP might be bound by 
glycogenin at the same site and, in turn, whether CDP-glucose 
might be a donor substrate. We decided to test all commercially 
available nucleoside diphosphate glucoses. 
We tested recombinant wild-type and Phe 194 glycogenins with 
ADP-glucose, CDP-glucose, GDP-glucose, TDP-glucose and 
UDP-glucose. Since these are not all available labelled with a 
radioisotope, we tested them as substrates for intermolecular 
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Fig. 1. Illustrating the nucleotide sugar specificity of glycogenin. The 
digests (100 gl each) contained 1/tM recombinant enzyme (wild-type 
in upper panel, Phe 194 mutant in lower panel) together with 10 mM 
nucleoside diphosphate glucose, 10 mM p-nitrophenyl a-maltoside, 
5 mM MnCI2 and 50 mM Tris-HC1 buffer, pH 7.4. After incubation for 
18 h at room temperature, a 10/21 portion of digest was loaded onto 
a C18 column and fractionated by reverse-phase HPLC using an as- 
cending gradient of acetonitrile (10-20%; 1 ml/min for 20 min). The 
sole, or right-hand, peak, in each case corresponds tothe p-nitrophenyl 
c~-maltoside substrate (M2) and, to the left of it the products of 
transglucosylation, p-nitrophenyl ~-maltotrioside (M3) and ~-mal- 
totetraoside (M4). They were detected by absorbance at320 nm. 
transglucosylation to p-nitrophenyl c~-maltoside and to assay 
the products by HPLC. The results are shown in Fig. 1. 
All three pyrimidine nucleoside diphosphate glucoses, but 
neither of the purine forms, acted as donor substrates. The 
formation ofp-nitrophenyl ~-maltotrioside was seen as a prod- 
uct of transfer and in each case this was utilized for the forma- 
tion ofp-nitrophenyl ct-maltotetraoside. M asuring the relative 
percentage utilization of the three glucose donors showed that 
CDP-glucose was used to 71% of the extent of UDP-glucose 
and TDP-glucose 33%. The results with the Phe 194 mutant were 
essentially identical (Fig. 1). The experiments were conducted 
with 10 mM glucose donors, incubated for 18 h, in order to 
form sufficient mass of product o quantitate by HPLC. 
Through the kindness of Dr. L. Roden, we obtained a sample 
of CDP-[]4C]glucose which we compared with UDP-[J4C]glu- 
cose at the usual 2 ¢tM concentration, using the wild-type n- 
zyme [13]. The relative initial-rate utilization of the CDP-glu- 
cose for self-glucosylation was the same 71% as observed at 
10 mM concentration for glucosylation ofp-nitrophenyl ~-mal- 
toside. 
As an added proof that glucose could be transferred to glyco- 
genin from these new donor substrates, we incubated them with 
recombinant glucose-free, apo-glycogenin [14] and examined 
the products by SDS-PAGE (Fig. 2). The average of 8 glucose 
residues added in self-glucosylation [14] is sufficient to cause the 
glucosylated protein to migrate at a distinctly lower rate than 
the glucose-free protein. Apo-glycogenin is compared before 
and after incubation with ADP-glucose and GDP-glucose in 
Fig. 2, (lanes 1,2,4, respectively). All three protein samples 
comigrated. When the same protein was incubated with CDP- 
glucose, TDP-glucose or UDP-glucose (lanes 3,5,6, respec- 
tively) they migrated more slowly than did apo-glycogenin (lane 
1). 
These experiments suggest hat glycogenin has a UDP-glu- 
cose binding site that can accommodate any of the three pyrim- 
idine nucleotides tested. The inability to utilize ADP-glucose or 
GDP-glucose, while undergoing inhibition by ATP (see above), 
suggests that the latter binds elsewhere. Our findings prompt 
an examination of the hypothesis with which we began, that 
CDP itself can compete with UDP-glucose for the latter's bind- 
ing site. 
So far as we are aware, CDP-glucose and TDP-glucose are 
not recognized as glucose donor substrates in mammalian me- 
tabolism. In Salmonella, CDP-glucose is the precursor of the 
3,6-dideoxyhexoses, paratose and ascarylose [19]. We do not 
therefore suggest that either of these glucose donors is a native 
substrate for mammalian glycogenin. The importance of the 
finding that CDP-glucose is an effective alternative to UDP- 
glucose is because CDP-glucose is not utilized by muscle glyco- 
gen synthase [20]. (TDP-glucose is used by synthase, at 5% of 
the rate of UDP-glucose [21].) That glycogenin can now be 
assayed with this specific substrate means that it will be possi- 
ble, either in tissue extracts, or in deliberate mixtures of homo- 
geneous glycogenin and synthase, to study glycogen synthesis 
sequentially by first creating the primer, with CDP-glucose, and 
then glycogen, with UDP-glucose. Such studies are necessary 
in order to understand what is required for the efficient initia- 
tion of glycogen synthesis. Cohen et al. [8,9] have claimed that 
a 'tight' 1:1 complex of glycogenin and synthase is required. In 
experiments in which they had dissociated native glycogenin 
and synthase, several hours were required for reassociation a d 
the extent of utilization of glycogenin increased as reassociation 
took place. Other workers, by contrast, fail to notice any 
requirement of recombinant glycogenin for time-dependent 
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Fig. 2. Depicting the ability of apo-glycogenin toself-glucosylate with 
pyrimidine but not purine nucleoside diphosphate glucoses. The digests 
(100/.d each) contained 1.35 gM recombinant apo-glycogenin [14], 100 
/2M nucleoside diphosphate glucose, plus MnC12 and buffer as in Fig. 
1. After incubation for 1 h at room temperature, an equal volume of 
20% trichloroacetic a id was added and the precipitates xamined by 
SDS-PAGE, the protein bands being revealed by Coomassie blue. The 
molecular masses of the standards (kDa) are shown on the left. Lane 
1, untreated apo-glycogenin; 2, incubated with ADP-glucose; 3, CDP- 
glucose; 4, GDP-glucose; 5, TDP-glucose; 6, UDP-glucose. 
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association with synthase in order for the former to prime the 
latter efficiently [15]. The use of glucose-free recombinant gly- 
cogenin (apo-glycogenin) [14], with CDP- and UDP-glucoses, 
and glycogen synthase, should enable the necessity, and the 
requirements, for complex formation to be explored. 
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